Adaptimmune Therapeutics plc
ADAP · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 87.7% | 126.1% | -92.1% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 81.7% | 87.9% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -192% | -585.6% | -2,109.7% | -31.4% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -221.8% | -653.2% | -2,303.4% | -43.1% |
| EPS Diluted | -0.12 | -0.19 | -0.29 | -0.069 |
| % Growth | 36.8% | 34.5% | -320.3% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |